Progyny (NASDAQ:PGNY) Issues Q3 2026 Earnings Guidance

Posted by George Bondi on Aug 6th, 2026

Progyny (NASDAQ:PGNY – Get Free Report) issued an update on its third quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.500-0.520 for the period, compared to the consensus EPS estimate of 0.470. The company issued revenue guidance of $335.0 million-$345.0 million, compared to the consensus revenue estimate of $350.2 million. Progyny also updated its FY 2026 guidance to 2.040-2.100 EPS.

Progyny Price Performance

Shares of PGNY stock traded down $1.16 during trading on Thursday, hitting $30.21. 1,863,949 shares of the stock traded hands, compared to its average volume of 1,465,451. Progyny has a 52-week low of $16.10 and a 52-week high of $33.06. The firm has a market capitalization of $2.37 billion, a P/E ratio of 39.23, a price-to-earnings-growth ratio of 2.50 and a beta of 1.01. The firm’s fifty day moving average price is $28.93 and its 200-day moving average price is $23.36.

Progyny (NASDAQ:PGNY – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $348.63 million. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities research analysts expect that Progyny will post 1.19 earnings per share for the current year.

Progyny announced that its board has authorized a stock buyback plan on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to buy up to 10.3% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

Several equities analysts recently issued reports on PGNY shares. Citizens Jmp increased their target price on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research note on Monday, May 11th. Barclays restated an “equal weight” rating and set a $34.00 target price (up from $27.00) on shares of Progyny in a research report on Tuesday, July 28th. Leerink Partners set a $38.00 price target on Progyny in a report on Wednesday, July 22nd. Wall Street Zen downgraded shares of Progyny from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Finally, Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Progyny presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.25.

Check Out Our Latest Analysis on Progyny

Insider Transactions at Progyny

In other Progyny news, Director Kevin K. Gordon sold 5,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total transaction of $137,445.00. Following the completion of the sale, the director directly owned 9,318 shares in the company, valued at $232,856.82. The trade was a 37.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Melissa B. Cummings sold 9,578 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total transaction of $239,450.00. Following the sale, the chief operating officer directly owned 73,371 shares of the company’s stock, valued at approximately $1,834,275. This trade represents a 11.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 36,916 shares of company stock valued at $939,875 in the last ninety days. Company insiders own 9.90% of the company’s stock.

Institutional Investors Weigh In On Progyny

A number of hedge funds have recently bought and sold shares of PGNY. Occudo Quantitative Strategies LP bought a new stake in Progyny in the fourth quarter valued at about $264,000. Inceptionr LLC bought a new stake in Progyny in the fourth quarter valued at $229,000. iSAM Funds UK Ltd acquired a new position in Progyny during the 3rd quarter valued at about $251,000. Aristides Capital LLC boosted its position in shares of Progyny by 4.6% during the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock worth $257,000 after buying an additional 528 shares during the period. Finally, Teza Capital Management LLC grew its stake in shares of Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after purchasing an additional 516 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

(Get Free Report)

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.